Measurement of PIP3 Levels Reveals an Unexpected Role for p110β in Early Adaptive Responses to p110α-Specific Inhibitors in Luminal Breast Cancer-Reference-Cited by-同舟云学术

Measurement of PIP3 Levels Reveals an Unexpected Role for p110β in Early Adaptive Responses to p110α-Specific Inhibitors in Luminal Breast Cancer

Published:2015-01 Issue:1 Volume:27 Page:97-108
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Costa Carlotta,Ebi Hiromichi,Martini Miriam,Beausoleil Sean A.,Faber Anthony C.,Jakubik Charles T.,Huang Alan,Wang Youzhen,Nishtala Madhuri,Hall Ben,Rikova Klarisa,Zhao Jean,Hirsch Emilio,Benes Cyril H.,Engelman Jeffrey A.

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference40 articles.

1. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics;Arteaga;Cancer Cell,2014

2. Cancer-specific mutations in PIK3CA are oncogenic in vivo;Bader;Proc. Natl. Acad. Sci. USA,2006

3. Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III phosphoinositide 3-kinase;Bago;Biochem J.,2014

4. Comparison of the kinetic properties of the lipid- and protein-kinase activities of the p110alpha and p110beta catalytic subunits of class-Ia phosphoinositide 3-kinases;Beeton;Biochem. J.,2000

5. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors;Chakrabarty;Proc. Natl. Acad. Sci. USA,2012

Cited by 168 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preclinical evaluation and phase 1 study of the PI3Kα/δ inhibitor TQ‐B3525 in Chinese patients with advanced cancers;Cancer;2024-06-26

2. Resistance to Targeted Inhibitors of the PI3K/AKT/mTOR Pathway in Advanced Oestrogen-Receptor-Positive Breast Cancer;Cancers;2024-06-18

3. Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models;Clinical Cancer Research;2024-05-31

4. A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation;Molecular Cancer;2024-03-14

5. Cell-Permeable Fluorescent Sensors Enable Rapid Live Cell Visualization of Plasma Membrane and Nuclear PIP3 Pools;JACS Au;2024-03-13